Search results for "Therapeutics."

showing 10 items of 480 documents

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

2020

Background: TAS-102 is an oral monotherapy, combining trifluridine and tipiracil hydrochloride, indicated for the treatment of pretreated metastatic colorectal cancer (mCRC). The aim of this real-life study is to evaluate the efficacy and safety of TAS-102 in heavily pretreated elderly patients with mCRC whose disease has progressed with standard therapies. Methods: In this retrospective observational study, we enrolled 50 elderly patients >70 years of age (median age 78 years) with a diagnosis of mCRC who were previously treated or were not considered candidates for treatment with other available therapies. Patients aged >70 years with advanced colorectal cancer and with an ECOG perf…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineECOG Performance StatusDiseasechemotherapyelderly patientstrifluridine/tipiracilQuality of lifeInternal medicinemedicinelonsurfOriginal ResearchPharmacologyChemotherapybusiness.industrymetastatic colorectal cancertrifluridine/ tipiracillcsh:RM1-950Retrospective cohort studyGeneral Medicinemedicine.diseaselcsh:Therapeutics. PharmacologyTolerabilityquality of lifetas-102Molecular Medicinebusinessmedicine.drugDrugs in Context
researchProduct

Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxici…

2020

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases. In addition, several studies indicate that MetS correlates with the increased risk of cancer in adults. The mechanisms linking MetS and cancer are not fully understood. Several risk factors involved in MetS are also cancer risk factors, such as the consumption of high calorie-food or high fat intake, low fibre intake, and sedentary lifestyle. Other common aspects of both cancer and MetS are oxidative stress and inflammation. In addition, some anticancer treatments can induce cardiotoxicity, including, for instance, left ventricular (LV) dysfunction and heart failure (HF), endothelial dysfunction an…

Oncologymedicine.medical_specialtyPhysiologyClinical BiochemistryReview030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineAgeing; Cancer; Cardiovascular disease; Cardiovascular toxicity from anticancer drugs; Metabolic syndromemedicineEndothelial dysfunctionRisk factorMolecular BiologySedentary lifestyleCancerCardiotoxicitybusiness.industrylcsh:RM1-950CancerCell Biologymedicine.diseaseCardiovascular diseaseMetabolic syndromeAgeingCardiovascular toxicity from anticancer drugslcsh:Therapeutics. PharmacologyCardiovascular toxicity from anticancer drug030220 oncology & carcinogenesisHeart failureMetabolic syndromebusinessOxidative stress
researchProduct

Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials

2018

We aimed to quantitatively synthesize data from randomized controlled trials (RCTs) concerning maintenance for multiple myeloma (MM). We searched electronic literature databases and conference proceedings to identify relevant RCTs. We selected eligible RCTs using predefined selection criteria. We conducted meta-analysis comparing maintenance containing new agents and conventional maintenance, and subgroup analysis by transplantation status and mainstay agent as well. We performed trial sequential analysis (TSA) to determine adequacy of sample size for overall and subgroup meta-analyses. We performed network meta-analysis (NMA) to compare and rank included regimens. A total of 22 RCTs involv…

Oncologymedicine.medical_specialtySubgroup analysismaintenancelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialMaintenance therapylawInternal medicinemedicinePharmacology (medical)030212 general & internal medicinenetwork meta-analysisOriginal ResearchLenalidomidePharmacologybusiness.industrylcsh:RM1-950Hazard ratioConfidence intervalmultiple myelomameta-analysisTransplantationtrial-sequential analysislcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesisMeta-analysisbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Post-therapeutic lymphedema in breast cancer

2019

Introductions. Lymphedema is an interstitial accumulation of protein-rich lymph fluid, due to the post-therapeutic alteration of lymphatic circulation in the upper limb. The appearance of lymphedema is favoured by a number of risk factors. All of these factors ultimately lead to a process of tissue fibrosis. Materials and methods. This study was carried out in an outpatient regimen, for a period of 12 months, in the kinetotherapy room, using massage elements for lymphatic drainage and kinetotherapy technique. The study group included 15 patients aged 27-65 years.Results and discutions. Patients evaluated the quality of life after surgery based on the physical and mental symptoms, which is w…

Oncologymedicine.medical_specialtybusiness.industrylcsh:RM1-950General Medicinelymphedema010402 general chemistrymedicine.disease01 natural scienceskinetotherapy technique0104 chemical scienceslymphatic drainage massage03 medical and health scienceslcsh:Therapeutics. Pharmacology0302 clinical medicineLymphedemaBreast cancer030220 oncology & carcinogenesisInternal medicinemedicinebusinessBalneo Research Journal
researchProduct

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct

Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy

2014

Francesco Saverio Mennini,1,2 Andrea Marcellusi,1,3 Massimo Andreoni,4 Antonio Gasbarrini,5 Salvatore Salomone,6 Antonio Craxì71Centre for Economic and International Studies (CEIS) – Economic Evaluation and HTA (EEHTA) Faculty of Economics, University of Rome Tor Vergata, Rome, Italy; 2Institute of Leadership and Management in Health, Kingston University, London, UK; 3Department of Demography, University of Rome La Sapienza, Rome, Italy; 4Department of Public Health and Cell Biology, School of Medicine, University of Rome Tor Vergata, Rome, Italy; 5Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rome, Italy; 6Department of…

Operations researchHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAEconomics Econometrics and Finance (miscellaneous)forecastcost of illnessmacromolecular substancesmedicine.disease_causeChronic hepatitisEnvironmental healthCost of illnessMedicineHealth policyOriginal Researchlcsh:R5-920business.industryHealth Policylcsh:RM1-950Health services researchvirus diseasesSettore SECS-S/04 - Demografianew HCV treatmentClinicoEconomics and Outcomes Researchlcsh:Therapeutics. Pharmacologychronic hepatitishepatitis Cbusinesslcsh:Medicine (General)ClinicoEconomics and Outcomes Research
researchProduct

Indicaxanthin from Opuntia ficus-indica Fruit Ameliorates Glucose Dysmetabolism and Counteracts Insulin Resistance in High-Fat-Diet-Fed Mice

2021

Obesity-related dysmetabolic conditions are amongst the most common causes of death globally. Indicaxanthin, a bioavailable betalain pigment from Opuntia ficus-indica fruit, has been demonstrated to modulate redox-dependent signalling pathways, exerting significant anti-oxidative and anti-inflammatory effects in vitro and in vivo. In light of the strict interconnections between inflammation, oxidative stress and insulin resistance (IR), a nutritionally relevant dose of indicaxanthin has been evaluated in a high-fat diet (HFD) model of obesity-related IR. To this end, biochemical and histological analysis, oxidative stress and inflammation evaluations in liver and adipose tissue were carried…

Opuntia ficus-indicaobesityPhysiologyindicaxanthin; <i>Opuntia ficus-indica</i>; phytochemicals; insulin resistance; obesity; inflammation; oxidative stress; dysmetabolismClinical BiochemistryindicaxanthinCell BiologyRM1-950phytochemicalsBiochemistryDysmetabolism<i>Opuntia ficus-indica</i>Oxidative stressinflammationinsulin resistanceTherapeutics. PharmacologyMolecular BiologyAntioxidants
researchProduct

Redox Systems, Oxidative Stress, and Antioxidant Defences in Health and Disease

2021

Reactive oxygen and nitrogen species (RONS) play a key role in the regulation of cell survival. While adequate levels of RONS are essential to sustain cell proliferation and survival, disruption of the endocellular redox state induces cell dysfunction and death. Indeed, under physiological conditions, a balance between the generation and elimination of RONS ensures the proper function of redox-sensitive signalling proteins. Conversely, alterations to the redox homeostasis may disrupt the function of key transcription factors, signaltransduction pathways and cell-death regulators. Along these lines, understanding the mechanisms underlying cellular redox homeostasis may help to develop nutrac…

Oxidative Stressn/aEditorialAntioxidant DefencesPhysiologyClinical BiochemistryCell BiologyTherapeutics. PharmacologyRM1-950Redox SystemsMolecular BiologyBiochemistryAntioxidants
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Impairment of PGC-1 Alpha Up-Regulation Enhances Nitrosative Stress in the Liver during Acute Pancreatitis in Obese Mice

2020

Acute pancreatitis is an inflammatory process of the pancreatic tissue that often leads to distant organ dysfunction. Although liver injury is uncommon in acute pancreatitis, obesity is a risk factor for the development of hepatic complications. The aim of this work was to evaluate the role of PGC-1&alpha

PGC-1&#9450301 basic medicineobesitymedicine.medical_specialtyAntioxidantacute pancreatitisPhysiologymedicine.medical_treatmentClinical BiochemistryPGC-1αAlpha (ethology)Nitrosative stressliverHepatic ComplicationBiochemistryArticle03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicineObesityMolecular BiologyLiver injurybusiness.industrylcsh:RM1-950Organ dysfunctionCell BiologyBiología y Biomedicina / Biologíamedicine.diseasenitrosative stressAcute pancreatitislcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologyLiver030220 oncology & carcinogenesisPancreatitisAcute pancreatitismedicine.symptombusinessAntioxidants
researchProduct